2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Lung Neoplasms
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma, Extra-Adrenal
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Osteosarcoma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
1
Gynecological Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Diseases
1
Interventions
Oxaliplatin
271
Fluorouracil
268
Capecitabine
234
Leucovorin
209
Irinotecan
152
Radiotherapy
138
Bevacizumab
114
Cetuximab
82
Surgical Procedures, Operative
51
Folfox protocol
48
Neoadjuvant Therapy
45
Drug Therapy
43
Radiation
42
Chemotherapy, Adjuvant
34
Chemoradiotherapy
34
Panitumumab
27
Magnetic Resonance Spectroscopy
26
XELOX
25
Radiotherapy, Intensity-Modulated
23
Biopsy
20
Surveys and Questionnaires
18
Laparoscopy
18
Proctectomy
17
Floxuridine
17
Early Intervention, Educational
16
Nivolumab
15
Immunohistochemistry
15
Gene Expression Profiling
15
Gemcitabine
15
pembrolizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
penpulimab
×
Clear all
NCT05576480
2025-08-28
SPARC
Ruijin Hospital
Phase 2
Recruiting
55 enrolled